Vertebroplasty provided quicker, stronger, and more durable pain relief from acute, osteoporotic vertebral compression fractures than did conservative pain management, judging from the findings of a randomized, open-label trial published online by the Lancet Aug. 10.
The article CDC Panel Recommends Against Using CSL Biotherapies Flu Vaccine in Children Under 8 (published Aug. 5) contained a error in the headline. The vaccine is indicated for children aged 6 months to 8 years, therefore the headline should have stated that the vaccine is for children under 9.
A pair of industry-funded multicenter studies has contributed to the growing call for infant vaccination against severe rotavirus gastroenteritis in the developing world.
The use of antiepileptic drugs does not appear to raise the risk of suicide beyond the increased risk already associated with the underlying conditions for which patients take these medicines, according to a report in the Aug. 5 issue of the New England Journal of Medicine.
Daily B vitamin supplementation is no more effective than is placebo for reducing the incidence of major vascular events in patients who have had a recent stroke or transient ischemic attack, according to findings from the Vitamins to Prevent Stroke () trial.
Provisions of the new Affordable Care , coupled with other payment changes, will save Medicare nearly $8 billion over 2 years and extend the solvency of the Medicare Trust by 12 years, according to a new report from the Centers for Medicare and Medicaid Services.
The Food and Drug Administration has approved influenza vaccines for the 2010-2011 flu season that protect against three influenza strains, including the 2009 H1N1 virus, the agency announced July 30.
ADELPHI, Md. (EGMN) A Food and Drug Administration advisory panel on July 29 voted 7 to 6 that a specific hemodynamic measure of response to drugs approved for pulmonary arterial hypertension in adults could be used to demonstrate the drugs efficacy in children with the disease, and to determine dosing in children.
COLLEGE PARK, Md. (EGMN) The Food and Drug Administrations Cardiovascular and Renal Drugs Advisory Committee on July 28 voted 7-1 to recommend approval of the platelet inhibitor ticagrelor to treat nonST elevation myocardial infarction and ST-elevation myocardial infarction in patients intended to receive primary coronary intervention or who would be managed medically.
Extending the time window for giving the recombinant tissue plasminogen activator alteplase toischemic stroke patients has increased the percentage of patients who are eligible to receive the thrombolytic therapy without causing treatment delays, according to a study published online July 27 in Lancet Neurology.
